0085-4324 : Noxafil 100 mg/1 Oral Tablet, Coated


NDC0085-4324
Labeler: Merck Sharp & Dohme Corp.
Product Type: Human Prescription Drug
Drug Name:  Noxafil
Dosage Form: Oral Tablet, Coated
Application #: NDA205053
Rev. Date: 


Appearance:


Markings: 100
Shapes:  Oval
Colors:  Yellow
Size (mm): 17
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

100: (0085-4324) Noxafil 100 mg/1 Oral Tablet, Coated by Merck Sharp & Dohme Corp.
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 0085-4324-02: 60 TABLET, COATED IN 1 BOTTLE (0085‑4324‑02)

Active Ingredients:

  • Posaconazole

Dosage Strength:

  • 100 mg

Inactive Ingredients:

  • Hypromellose Acetate Succinate 06081224 (3 Mm2/S)
  • Cellulose, Microcrystalline
  • Hydroxypropyl Cellulose (Type H)
  • Silicon Dioxide
  • Croscarmellose Sodium
  • Magnesium Stearate
  • Polyvinyl Alcohol
  • Polyethylene Glycol 3350
  • Titanium Dioxide
  • Talc
  • Ferric Oxide Yellow

Pharmaceutical Classes:

  • Azole Antifungal [EPC]
  • Azoles [CS]

Related Products:

Based on records with the same trade name.
  • 0085-1328 Noxafil 40 mg/ml Oral Suspension by Merck Sharp & Dohme Corp.
  • 0085-2224 Noxafil 300 mg Oral Powder, for Suspension by Merck Sharp & Dohme Corp.
  • 0085-4331 Noxafil 18 mg/ml Intravenous Solution by Merck Sharp & Dohme Corp.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0085-4324 QR Code

< Prev: 0085-4320Next: 0085-4331 >




Note: The MedsChat® NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.